Overexpression of genes on 16q associated with cisplatin resistance of testicular germ cell tumor cell lines

被引:19
作者
Wilson, C
Yang, JS
Strefford, OC
Summersgil, B
Young, BD
Shipley, J
Oliver, T
Lu, YJ
机构
[1] Queen Mary Univ London, Barts & London Sch Med & Dent, Dept Med Oncol, London EC1M 6BQ, England
[2] Inst Canc Res, Sutton, Surrey, England
关键词
D O I
10.1002/gcc.20173
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Testicular germ-cell tumors (TGCTs) show exquisite sensitivity to cisplatin-based chemotherapy, and therefore this is considered a good model system for studying the mechanism of chemotherapy resistance. Although the genetic alterations related to TGCT have been well studied, little is known about the genetic basis of chemotherapy resistance, which occurs in a small proportion of TGCTs. In this study, we investigated genomic and expression differences between three cisplatin-sensitive and their paired cisplatin-resistant lines using combined whole-genome screen approaches. Comparative genomic hybridization (CGH) analysis on chromosomes revealed genetic differences between the resistant and parent cell lines in each pair, but did not show any consistent chromosome changes in all three lines. Microarray CGH analysis generated some additional information of DNA copy number gains and losses including some important oncogenes, tumor-suppressor genes, and drug-resistance-related genes. However, no consistent genomic region changes were found in the three cell lines. Interestingly, when comparative expressed sequence hybridization, a technique for gene expression profiling along chromosomes, was applied, we discovered a consistently overexpressed chromosomal region in all three resistant lines compared with their parent lines. The minimum overlapping chromosomal region is at 16q22-23. Further definition of genes in this chromosomal region will aid our understanding of the mechanism of cisplatin resistance and may offer novel therapeutic targets. (c) 2005 Wiley-Liss, Inc.
引用
收藏
页码:211 / 216
页数:6
相关论文
共 48 条
[1]   DNA copy number changes and evaluation of MYC, IGF1R, and FES amplification in xenografts of pancreatic adenocarcinoma [J].
Armengol, G ;
Knuutila, S ;
Lluís, F ;
Capellà, G ;
Miró, R ;
Caballín, MR .
CANCER GENETICS AND CYTOGENETICS, 2000, 116 (02) :133-141
[2]   Testicular germ-cell cancer [J].
Bosl, GJ ;
Motzer, RJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (04) :242-253
[3]   THE USE OF TUMOR-MARKERS IN GERM-CELL MALIGNANCIES [J].
BOSL, GJ ;
CHAGANTI, RSK .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1994, 8 (03) :573-587
[4]  
BRONSON DL, 1980, CANCER RES, V40, P2500
[5]  
Burger H, 1999, INT J CANCER, V81, P620, DOI 10.1002/(SICI)1097-0215(19990517)81:4<620::AID-IJC19>3.0.CO
[6]  
2-S
[7]  
Chaganti RSK, 2000, CANCER RES, V60, P1475
[8]   E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? [J].
Cleton-Jansen, AM .
BREAST CANCER RESEARCH, 2002, 4 (01) :5-8
[9]   Growth regulatory factors and signalling proteins in testicular germ cell tumours [J].
Devouassoux-Shisheboran, M ;
Mauduit, C ;
Tabone, E ;
Droz, JP ;
Benahmed, M .
APMIS, 2003, 111 (01) :212-224
[10]   Genetic profiling of colorectal cancer liver metastases by combined comparative genomic hybridization and G-banding analysis [J].
Diep, CB ;
Parada, LA ;
Teixeira, MR ;
Eknæs, M ;
Nesland, JM ;
Johansson, B ;
Lothe, RA .
GENES CHROMOSOMES & CANCER, 2003, 36 (02) :189-197